Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 726153
                    [Title] => New treatment option for advanced breast cancer
                    [Summary] => 
GlaxoSmithKline Philippines (GSK) recently announced the Philippine Food and Drug Administration approval of a new indication for its targeted therapy Lapatinib in combination with paclitaxel, a widely used chemotherapy agent.
                    [DatePublished] => 2011-09-13 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

        )

)

ONCOLOGY CONGRESS

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 726153
                    [Title] => New treatment option for advanced breast cancer
                    [Summary] => 
GlaxoSmithKline Philippines (GSK) recently announced the Philippine Food and Drug Administration approval of a new indication for its targeted therapy Lapatinib in combination with paclitaxel, a widely used chemotherapy agent.
                    [DatePublished] => 2011-09-13 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

        )

)

abtest

New treatment option for advanced breast cancer

September 13, 2011 - 12:00am

GlaxoSmithKline Philippines (GSK) recently announced the Philippine Food and Drug Administration approval of a new indication for its targeted therapy Lapatinib in combination with paclitaxel, a widely used chemotherapy...

Health And Family